Importantly, we observed increased MM-specific CD8+ Tc cells expansion and selective anti-MM immune activities after anti-GAL-3 treatment of both MM patient BMMC and XBP1/CD138/CS1-specific CTL. This evidence concerns the gene CD8A and Miyoshi myopathy.